YMAB / Y-mAbs Therapeutics receives 'Neutral' stance from Wedbush after FDA rejection of its pediatric cancer drug application

Y-mAbs Therapeutics is undervalued despite growing sales of their approved cancer therapy, presenting an opportunity for investors. Their approved pro more_horizontal

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2023 Earnings Call Transcript August 11, 2023 9:00 AM ET Company Participants Courtney Dugan - Head of IR more_horizontal

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compar more_horizontal

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants Thomas Gad - Founder, President, more_horizontal

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compar more_horizontal

The consensus price target hints at an 111.1% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-a more_horizontal

Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions m more_horizontal

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do more_horizontal